KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Deferred Revenue (2016 - 2025)

Moderna (MRNA) has disclosed Current Deferred Revenue for 10 consecutive years, with $99.0 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 35.29% to $99.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $99.0 million through Dec 2025, down 35.29% year-over-year, with the annual reading at $99.0 million for FY2025, 35.29% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $99.0 million at Moderna, down from $320.0 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $8.5 billion in Q3 2021, with the low at $20.0 million in Q2 2024.
  • Average Current Deferred Revenue over 5 years is $2.7 billion, with a median of $1.6 billion recorded in 2023.
  • The sharpest move saw Current Deferred Revenue skyrocketed 16039.16% in 2021, then plummeted 98.85% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $6.3 billion in 2021, then plummeted by 56.64% to $2.7 billion in 2022, then plummeted by 79.05% to $568.0 million in 2023, then plummeted by 73.06% to $153.0 million in 2024, then tumbled by 35.29% to $99.0 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $99.0 million, $320.0 million, and $218.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.